ALK 重排肺腺癌的临床病理特征概述及 ALK 重排的现行诊断检测方法。
Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.
机构信息
1 Department of Pathology, Seoul National University Hospital, College of Medicine, Seoul, Korea ; 2 Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
出版信息
Transl Lung Cancer Res. 2015 Apr;4(2):149-55. doi: 10.3978/j.issn.2218-6751.2014.12.02.
Abstract
Patients with non-small cell lung cancer (NSCLC) who harbor anaplastic lymphoma kinase (ALK) gene rearrangements can derive significant clinical benefit from ALK tyrosine kinase inhibitor. Accurate patient identification is absolutely crucial for successful using ALK inhibitor treatment. However, lung cancer patients with ALK gene rearrangement after ALK inhibitor therapy eventually develop acquired resistance to treatment. In this review, the authors summarize the clinicopathologic features of ALK-rearranged NSCLC and the pros and cons of current diagnostic testing. In addition, we discuss the current diagnostic flow of ALK testing and consideration of rebiopsy sample during disease progression in patients treated by ALK inhibitors.
摘要
非小细胞肺癌（NSCLC）患者如果存在间变性淋巴瘤激酶（ALK）基因重排，可以从 ALK 酪氨酸激酶抑制剂中获得显著的临床获益。准确识别患者对于成功使用 ALK 抑制剂治疗至关重要。然而，ALK 抑制剂治疗后发生 ALK 基因重排的肺癌患者最终会对治疗产生获得性耐药。在这篇综述中，作者总结了 ALK 重排 NSCLC 的临床病理特征以及当前诊断检测的优缺点。此外，我们还讨论了在接受 ALK 抑制剂治疗的患者疾病进展期间，ALK 检测的当前诊断流程以及重新活检样本的考虑因素。
相似文献
1
Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.ALK 重排肺腺癌的临床病理特征概述及 ALK 重排的现行诊断检测方法。
Transl Lung Cancer Res. 2015 Apr;4(2):149-55. doi: 10.3978/j.issn.2218-6751.2014.12.02.
2
Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.非小细胞肺癌（NSCLC）中间变性淋巴瘤激酶（ALK）基因重排：多中心 ALK 检测结果。
Lung Cancer. 2013 Aug;81(2):200-6. doi: 10.1016/j.lungcan.2013.04.015. Epub 2013 May 10.
3
Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.非小细胞肺癌中循环肿瘤细胞与肿瘤组织间间变性淋巴瘤激酶（ALK）基因重排的一致性
Oncotarget. 2016 Apr 26;7(17):23251-62. doi: 10.18632/oncotarget.8136.
4
Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.间变性淋巴瘤激酶（ALK）重排的肺鳞状细胞癌的临床特征：一项回顾性分析与综述
Oncotarget. 2018 May 8;9(35):24000-24013. doi: 10.18632/oncotarget.25257.
5
Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.具有间变性淋巴瘤激酶重排的非小细胞肺癌的计算机断层扫描成像特征：系统评价和荟萃分析。
Clin Lung Cancer. 2019 Sep;20(5):339-349. doi: 10.1016/j.cllc.2019.05.006. Epub 2019 May 11.
6
ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.从不吸烟者和长期戒烟者中的ALK+肺腺癌：患病率及免疫组织化学和荧光原位杂交检测
Virchows Arch. 2016 Nov;469(5):533-540. doi: 10.1007/s00428-016-2005-y. Epub 2016 Aug 25.
7
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.综合基因组分析鉴定出一组荧光原位杂交未检测到的对克唑替尼敏感的ALK重排非小细胞肺癌。
Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.
8
Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?非小细胞肺癌与病理学中的精准医疗：ALK 在其中的作用途径如何？
Ann Oncol. 2016 Sep;27 Suppl 3:iii16-iii24. doi: 10.1093/annonc/mdw302.
9
Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples.非小细胞肺癌中间变性淋巴瘤激酶基因重排的异质性：小活检与切除标本的比较研究。
J Thorac Oncol. 2015 May;10(5):800-805. doi: 10.1097/JTO.0000000000000507.
10
Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.非小细胞肺癌细胞学样本中间变性淋巴瘤激酶基因重排：与组织学评估的比较。
Cancer Cytopathol. 2014 Jun;122(6):445-53. doi: 10.1002/cncy.21418. Epub 2014 Mar 19.
引用本文的文献
1
Clinicopathological Features of Non-Small Cell Lung Carcinoma with NRAS Mutation.具有NRAS突变的非小细胞肺癌的临床病理特征
J Pers Med. 2025 May 16;15(5):199. doi: 10.3390/jpm15050199.
2
Real-world data on ALK rearrangement test in Chinese advanced non-small cell lung cancer (RATICAL): a nationwide multicenter retrospective study.中国晚期非小细胞肺癌中 ALK 重排检测的真实世界数据（RATICAL）：一项全国多中心回顾性研究。
Cancer Commun (Lond). 2024 Sep;44(9):992-1004. doi: 10.1002/cac2.12593. Epub 2024 Jul 17.
3
A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy.间变性淋巴瘤激酶（ALK）重排与突变的研究进展：对胃癌发生机制及靶向治疗的启示
Curr Protein Pept Sci. 2024;25(7):539-552. doi: 10.2174/0113892037291318240130103348.
4
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.EML4-ALK 融合通过 JAK-STAT 激活驱动肺腺鳞转化。
J Exp Med. 2024 Mar 4;221(3). doi: 10.1084/jem.20232028. Epub 2024 Jan 29.
5
Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies.了解针对非小细胞肺癌的化疗和免疫治疗靶点的可行性：耐药反应及近期联合治疗的最新进展
Explor Target Antitumor Ther. 2023;4(5):850-895. doi: 10.37349/etat.2023.00171. Epub 2023 Oct 10.
6
Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment.对抗谱系特异性转录因子网络通过重塑肿瘤免疫微环境来精细调节肺腺癌向鳞癌的转分化。
Natl Sci Rev. 2023 Feb 14;10(4):nwad028. doi: 10.1093/nsr/nwad028. eCollection 2023 Apr.
7
Performance Characteristics of Oncomine Focus Assay for Theranostic Analysis of Solid Tumors, A (21-Months) Real-Life Study.Oncomine焦点分析在实体瘤治疗诊断分析中的性能特征：一项为期21个月的实际研究
Diagnostics (Basel). 2023 Mar 1;13(5):937. doi: 10.3390/diagnostics13050937.
8
Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement.ALK 重排的早期非小细胞肺癌患者的临床病理和计算机断层扫描特征。
Cancer Imaging. 2023 Feb 23;23(1):20. doi: 10.1186/s40644-023-00537-y.
9
Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib.阿来替尼治疗脑转移的 ALK 阳性非小细胞肺癌患者中枢神经系统临床基因组结局的特征。
Lung Cancer. 2023 Apr;178:57-65. doi: 10.1016/j.lungcan.2023.02.005. Epub 2023 Feb 9.
10
Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms.利用深度学习算法从苏木精和伊红染色切片中直接鉴定非小细胞肺癌中的 ALK 和 ROS1 融合。
Mod Pathol. 2022 Dec;35(12):1882-1887. doi: 10.1038/s41379-022-01141-4. Epub 2022 Sep 3.
本文引用的文献
1
Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma.致癌基因突变与组织学亚型相关，但在肺腺癌中无独立的预后价值。
Onco Targets Ther. 2014 Aug 13;7:1423-37. doi: 10.2147/OTT.S58900. eCollection 2014.
2
Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.在接受 TKI 治疗的致癌基因依赖性 NSCLC 患者疾病进展期间进行再次活检。
Target Oncol. 2015 Jun;10(2):247-53. doi: 10.1007/s11523-014-0332-y. Epub 2014 Aug 15.
3
Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.510 例韩国非小细胞肺癌患者 EGFR、KRAS 和 ALK 基因分型的同时诊断平台凸显了晚期患者中 ALK 重排率显著更高。
J Surg Oncol. 2014 Sep;110(3):245-51. doi: 10.1002/jso.23646. Epub 2014 May 29.
4
ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.一大系列连续非小细胞肺癌中的ALK重排：一种新的免疫组织化学方法与荧光原位杂交在筛选适合克唑替尼治疗患者方面的比较
Arch Pathol Lab Med. 2014 Nov;138(11):1449-58. doi: 10.5858/arpa.2013-0388-OA. Epub 2014 Jun 2.
5
An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.一项使用ALK免疫组化抗体D5F3和灵敏检测试剂盒的国际解读研究表明，ALK免疫组化与ALK荧光原位杂交之间以及评估者之间具有高度一致性。
J Thorac Oncol. 2014 May;9(5):631-8. doi: 10.1097/JTO.0000000000000115.
6
Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.非小细胞肺癌常规病理样本中肿瘤基因分型技术的成功率和失败率。
Lung Cancer. 2014 Apr;84(1):39-44. doi: 10.1016/j.lungcan.2014.01.013. Epub 2014 Jan 28.
7
A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype.基于驱动癌基因突变的ALK重排肺腺癌组织形态学特征的综合比较分析：上皮-间质转化标志物的表达比其他基因型更频繁。
PLoS One. 2013 Oct 23;8(10):e76999. doi: 10.1371/journal.pone.0076999. eCollection 2013.
8
Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer.免疫组织化学可在晚期非小细胞肺癌患者中可靠地检测到 ALK 重排。
Virchows Arch. 2013 Oct;463(4):583-91. doi: 10.1007/s00428-013-1472-7. Epub 2013 Aug 18.
9
Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.新型全自动免疫化学检测在原发性肺腺癌中检测 ALK 重排的诊断价值。
Ann Oncol. 2013 Oct;24(10):2589-2593. doi: 10.1093/annonc/mdt295. Epub 2013 Jul 31.
10
Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.检测肺腺癌中的 ALK 重排：免疫组织化学和荧光原位杂交的多中心比较。
Mod Pathol. 2013 Dec;26(12):1545-53. doi: 10.1038/modpathol.2013.87. Epub 2013 Jun 7.
Zotero 插件